# US 2021/0228614 A1 · LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228614 A1
- Document ID: US20210228614A1
- Status: Published application
- Kind: A1
- Application number: 17/106,259
- Filed: 2020-11-30
- Published: 2021-07-29
- Earliest claimed: 2017-07-13
- Assignees: Alnylam Pharmaceuticals, Inc.; The UAB Research Foundation
- Applicants: Alnylam Pharmaceuticals, Inc.; The UAB Research Foundation
- Inventors: David Erbe; Abigail Liebow; Kevin Fitzgerald; Gregory Hinkle; Kyle David Wood; Ross Philip Holmes; John Knight
- Web page: https://patentgrep.com/patent/US20210228614A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Y 101/03015: (S)-2-Hydroxy-acid oxidase (1.1.3.15)
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/3125: Methylphosphonates
- C12N 2310/313: Phosphorodithioates
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2310/3521: Methyl
- C12N 2310/3523: Allyl
- C12N 2310/3525: MOE, methoxyethoxy
- C12Y 101/01027: L-Lactate dehydrogenase (1.1.1.27)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting expression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.

## Claims

### Claim at position 1

-3. (canceled)

### Claim 4 (depends on 31)

The dsRNA agent of claim 31, wherein at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, a nucleotide comprising a 5′-phosphate mimic, a glycol modified nucleotide, and a 2-O—(N-methylacetamide) modified nucleotide, and combinations thereof.

### Claim 5 (depends on 31)

The dsRNA agent of claim 31, wherein the modified nucleotides are selected from the group consisting of a 2′-O-methyl modified nucleotide and a 2′-fluoro modified nucleotide.

### Claim 6 (depends on 31)

The dsRNA agent of claim 31, wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide.

### Claim 7 (depends on 31)

The dsRNA agent of claim 31, wherein the agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

### Claim 8 (depends on 7)

The dsRNA agent of claim 7, wherein the sense strand comprises at least one phosphorothioate internucleotide linkage at the 3′terminus.

### Claim 9 (depends on 7)

The dsRNA agent of claim 7, wherein the antisense strand comprises at least one phosphorothioate internucleotide linkage at the 3′terminus

### Claim 10 (depends on 31)

The dsRNA agent of claim 31, wherein the ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.

### Claim 11

(canceled)

### Claim 12 (depends on 31)

The dsRNA agent of claim 31 wherein said double stranded region comprises 20 nucleotides.

### Claim 13 (depends on 31)

The dsRNA agent of claim 31, wherein said double stranded region exhibits 100% complementarity between the sense and antisense strands.

### Claim 14

(canceled)

### Claim 15 (depends on 31)

The dsRNA agent of claim 31, wherein the dsRNA agent is capable of knocking down LDHA expression by at least 80% in a cell when provided as a single dose of 10 nM to the cell.

### Claim 16 (depends on 31)

The dsRNA agent of claim 31, wherein the antisense strand is 22 nucleotides in length.

### Claim 17 (depends on 31)

A cell containing the dsRNA agent of claim 31.

### Claim 18 (depends on 31)

A pharmaceutical composition for inhibiting expression of a lactic acid dehydrogenase A (LDHA) gene comprising the dsRNA agent of claim 31.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 18, 31)

A method of inhibiting lactic acid dehydrogenase A (LDHA) expression in a cell, the method comprising contacting the cell with the dsRNA agent of claim 31, or the pharmaceutical composition of claim 18, thereby inhibiting expression of LDHA in the cell.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cell is within a subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the subject is a human.

### Claim 24 (depends on 21)

The method of claim 21, wherein the LDHA expression is inhibited by at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95%, or to below the level of detection of LDHA expression.

### Claim 25 (depends on 23)

The method of claim 23, wherein the human subject suffers from an oxalate pathway-associated disease, disorder, or condition.

### Claim 26 (depends on 25)

The method of claim 25, wherein the oxalate pathway-associated disease, disorder, or condition is an oxalate-associated disease, disorder, or condition, or a lactate dehydrogenase-associated disease, disorder, or condition.

### Claim 27 (depends on 26)

The method of claim 26, wherein the oxalate-associated disease, disorder, or condition is a kidney stone formation disease, disorder, or condition, or a calcium oxalate tissue deposition disease, disorder, or condition.

### Claim 28 (depends on 26)

The method of claim 26, wherein the lactate dehydrogenase-associated disease, disorder, or condition is selected from the group consisting of cancer, fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), cirrhosis of the liver, accumulation of fat in the liver, inflammation of the liver, hepatocellular necrosis, liver fibrosis, and nonalcoholic fatty liver disease (NAFLD).

### Claim 29

(canceled)

### Claim 30 (depends on 18, 31)

A method of treating a subject having a disorder that would benefit from a reduction in LDHA expression, the method comprising
administering to the subject a therapeutically effective amount of the dsRNA agent of claim 31, or the pharmaceutical composition of claim 18, thereby treating the subject.

### Claim 31

A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of lactic acid dehydrogenase A (LDHA) in a cell,
wherein the dsRNA agent comprises a sense strand and an antisense strand,
wherein the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense nucleotide sequences listed in any one of Tables 2-5,
wherein the antisense strand is 19-23 nucleotides in length,
wherein all of the nucleotides of the sense strand are modified nucleotides
wherein all of the nucleotides of the antisense strand are modified nucleotides, and
wherein a ligand comprising one or more N-acetylgalactosamine (GalNAc) derivatives attached through a monovalent, bivalent, or trivalent branched linker is conjugated to at least one strand of the agent.
